MedTrace Logo

Evaluation of the Impact of Medium-chain Fatty Acids in the Evolution of Newly Diagnosed Mild Cognitive Impairment

NCT06951932 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-05-04

No results posted yet for this study

Summary

Mild cognitive impairment (MCI) is considered the intermediate stage between the changes observed in physiological aging and dementia. Currently, there is no drug therapy, and available drugs offer only minimal benefit on symptoms, only partially slowing the course of the condition. Studies in the literature have investigated the role of omega-3 fatty acids in MCI, and when administered over a period of six months, they appear to improve clinical condition and mood. In addition, medium-chain triglycerides (MCTs) appear to exert an antioxidant function, enhance cognitive ability in patients with MCI or Alzheimer's, and promote deep sleep state.

Conditions

  • Mild Cognitive Impairment (MCI)

Interventions

DIETARY_SUPPLEMENT

Mediterranean-type diet with MCT supplementation

The treatment arm will follow a Mediterranean diet supplemented by daily intake of MCT (30 mL)

OTHER

Mediterranean-type food regimen using extra virgin olive oil

The arm will follow a Mediterranean diet with an indication to take extra virgin olive oil as the main fat in the diet daily

Sponsors & Collaborators

  • Dr. Schär AG / SPA

    collaborator INDUSTRY

  • Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-03
Primary Completion
2025-07-03
Completion
2025-11-03

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06951932 on ClinicalTrials.gov